drugset
drugset / Trial / NCT06124144

Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults

NCT06124144 ↗

Phase 1 Terminated 13 enrolled University Hospital Tuebingen
NaSingle-groupOpen-labelTreatment

Summary

The goal of this interventional study is to assess the safety and tolerability of OlPC and to characterize the pharmacokinetics (PK) of OlPC following single, ascending doses administered orally in healthy-fed subjects.

Timeline

Start
2023-06-21
Primary completion
2024-02-27
Completion
2024-02-27

Outcome

Outcome not reported

Stopped: “The risk-benefit ratio changed”

Drugs

EvaluationDrugModalityDoseRoute
Subject Oleylphosphocholine Small molecule 50 mg Oral
Subject Oleylphosphocholine Small molecule 100 mg Oral
Subject Oleylphosphocholine Small molecule 150 mg Oral
Subject Oleylphosphocholine Small molecule 200 mg Oral
Subject Oleylphosphocholine Small molecule 250 mg Oral
Subject Oleylphosphocholine Small molecule 300 mg Oral

Indications

leishmaniasis